#United States #Class Action #Edwards Lifesciences #Los Angeles #Bernard Zovighian

Important Notice Regarding Class Action Settlement

On September 8, 2026, Kroll Settlement Administration LLC issued a statement regarding the Patel v. Edwards Lifesciences Corp. class action lawsuit currently pending in the United States District Court for the Central District of California. This legal action pertains to a group of investors who acquired common stock in Edwards Lifesciences Corporation between February 6, 2024, and July 24, 2024.

Background of the Case

The lawsuit was mainly initiated by two lead plaintiffs, the City of Fort Lauderdale Police and Firefighters’ Retirement System and the Louisiana Sheriffs’ Pension and Relief Fund. They allege that the company and its CEO, Bernard J. Zovighian, made materially false and misleading statements about the company's core product, the transcatheter aortic valve replacement (TAVR) platform, during the specified period, which they claim led to significant investor losses. The plaintiffs argue that these statements violated federal securities laws, specifically Section 10(b) of the Securities Exchange Act of 1934.

Despite the claims, Edwards Lifesciences and Zovighian deny any wrongdoing, asserting that no valid claims have been established against them and contesting the allegations.

Proposed Settlement Details

The lead plaintiffs have reached a proposed settlement of $39 million aimed at resolving all claims brought in the Action. This settlement, however, is contingent upon court approval. A Settlement Hearing is scheduled for December 16, 2026. During this session, the court will evaluate various aspects, such as whether the settlement terms are fair and reasonable for affected class members, whether the class defined as the Settlement Class should be certified, and whether class representatives and counsel are suitably appointed.

What Affected Investors Need to Know

Investors who acquired Edwards Lifesciences’ stock during the class period should pay close attention to the notices being distributed, as their rights may be influenced by the proceedings. Members of the Settlement Class may be entitled to share in the settlement proceeds, but participation requires filing a Claim Form. This form must be submitted online or postmarked no later than December 2, 2026. Details for submitting claims and the full settlement notice are available on the settlement website.

Options for Class Members

Those who do not wish to be part of the settlement have the option to exclude themselves, which must also be done by the deadline of December 2, 2026. Moreover, any objections to the proposed settlement must be formally filed with the Court by the same date.

Important Dates to Remember

• - Settlement Hearing: December 16, 2026, at 1:30 PM PT.
• - Claim Form Submission Deadline: December 2, 2026.
• - Exclusion Request Deadline: December 2, 2026.
• - Objection Deadline: December 2, 2026.

To summarize, eligible investors are encouraged to carefully review the provided notice and decide on their course of action concerning the proposed settlement. They should consult the settlement website, contact the claims administrator, or seek legal advice if necessary. It is crucial to act promptly in order to preserve your rights.